From prayer times to family vigils, everyday realities can alter how delirium presents — and how clinicians should respond.

Roughly 25 percent of dementia patients were prescribed at least one ‘potentially inappropriate’ drug between 2013 and 2021 ...

The Sunnyvale, CA-based firm's EEG-based solution uses artificial intelligence algorithms to identify large vessel occlusion ...

Ceribell announced today that the FDA granted breakthrough device designation for its large vessel occlusion (LVO) stroke ...

Issued on behalf of VentriPoint Diagnostics Ltd. Dana Friesen, CEO of Summit Sciences, brings over 15 years of experience in financial analysis and ROI optimization within the medical device and ...

Ceribell’s LVO Stroke tool is underpinned by the same EEG monitoring technology used in its seizure and delirium monitoring ...

Issued on behalf of VentriPoint Diagnostics Ltd. VANCOUVER –Baystreet.ca News Commentary – The healthcare AI market reached $21.66 billion in 2025 and analysts now project growth to $110.61 billion by ...

Ceribell wins FDA Breakthrough status for its AI-driven EEG solution to detect and monitor LVO strokes in hospitals, boosting credibility and growth outlook.

Clearance would position the Ceribell System as the first and only point-of-care electroencephalography (EEG) technology to ...

In elderly patients, neurosurgery must ultimately be judged not by what it corrects on imaging, but by what it preserves in ...

Let’s be clear. The primary reason to be vaccinated against shingles is that two shots provide 90 percent protection against ...

Investing.com -- CeriBell, Inc. (NASDAQ:CBLL) stock jumped 8% on Monday after the medical technology company announced it received FDA Breakthrough Device Designation for its Large Vessel Occlusion ...